Schrodinger Inc (NAS:SDGR)

$ 20.59 0.01 (0.05%) Market Cap: 1.50 Bil Enterprise Value: 1.24 Bil PE Ratio: 0 PB Ratio: 3.16 GF Score: 78/100

Q2 2024 Schrodinger Inc Earnings Call Transcript
Jul 31, 2024

$22.28 (-1.28%)

Earnings
Q1 2024 Schrodinger Inc Earnings Call Transcript
May 01, 2024

$25.26 (+3.61%)

Earnings
Q4 2023 Schrodinger Inc Earnings Call Transcript
Feb 28, 2024

$31.37 (-5.20%)

Earnings
Schrodinger Inc to Host Pipeline Day Transcript
Dec 14, 2023
Q3 2023 Schrodinger Inc Earnings Call Transcript
Nov 01, 2023

$21.82 (+0.53%)

Earnings
Schrodinger Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Q2 2023 Schrodinger Inc Earnings Call Transcript
Aug 02, 2023

$50.24 (-3.99%)

Earnings
Schrodinger Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Schrodinger Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Q1 2023 Schrodinger Inc Earnings Call Transcript
May 04, 2023

$30.12 (+3.33%)

Earnings
Q4 2022 Schrodinger Inc Earnings Call Transcript
Feb 28, 2023

$21.73 (+1.12%)

Earnings
Q3 2022 Schrodinger Inc Earnings Call Transcript
Nov 03, 2022

$24.66 (+0.65%)

Earnings
Schrodinger Inc Platform Day Transcript
Oct 06, 2022
Schrodinger Inc at Citi BioPharma Conference Transcript
Sep 07, 2022
Q2 2022 Schrodinger Inc Earnings Call Transcript
Aug 04, 2022

$34.71 (+4.96%)

Earnings
Schrodinger Inc at Citi Biopharma Co-Panel Day (Virtual) Transcript
May 18, 2022
Q1 2022 Schrodinger Inc Earnings Call Transcript
May 04, 2022

$26.88 (+2.99%)

Earnings
Q4 2021 Schrodinger Inc Earnings Call Transcript
Feb 24, 2022

$27.4 (+10.31%)

Earnings
Schrodinger Inc at Goldman Sachs Byte-ology Conference (Virtual) Transcript
Dec 09, 2021
Schrodinger Inc at Piper Sandler Healthcare Conference (Virtual) Transcript
Nov 22, 2021
Q3 2021 Schrodinger Inc Earnings Call Transcript
Nov 10, 2021

$51.16 (-4.98%)

Earnings
Schrodinger Inc at Bank of America Tech Solutions for Drug Discovery Conference (Virtual) Transcript
Sep 20, 2021
Schrodinger Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Q2 2021 Schrodinger Inc Earnings Call Transcript
Aug 12, 2021

$59.37 (-5.54%)

Earnings
Schrodinger Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 08, 2021
Schrodinger Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 11, 2021
Q1 2021 Schrodinger Inc Earnings Call Transcript
May 11, 2021

$61.74 (-3.55%)

Earnings
Schrodinger Inc Review Data Presented From CDC7 Program At (AACR) Annual Meeting - Corporate Call Transcript
Apr 12, 2021
Schrodinger Inc at Credit Suisse Healthcare Innovators Series : AI/Biotech Event Transcript
Mar 23, 2021
Q4 2020 Schrodinger Inc Earnings Call Transcript
Mar 04, 2021

$72.59 (-26.78%)

Earnings
Q3 2020 Schrodinger Inc Earnings Call Transcript
Nov 12, 2020

$52.69 (+2.45%)

Earnings
Schrodinger Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 15, 2020
Q2 2020 Schrodinger Inc Earnings Call Transcript
Aug 10, 2020

$74.26 (+4.34%)

Earnings
Q1 2020 Schrodinger Inc Earnings Call Transcript
May 13, 2020

$55.47 (-5.55%)

Earnings

Q3 2023 Schrodinger Inc Earnings Call Transcript

Nov 01, 2023 / 08:30PM GMT

Release Date Price: $21.82 (+0.53%)

Transcript 10-Q8-K

Operator

Thank you for standing by. Welcome to Schrodinger's conference call to review third quarter 2023 financial results. My name is Eric and I'll be your operator for today's call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

Now I would like to introduce your host for today's conference, Ms. Jaren Madden, Senior Vice President of Investor Relations and Corporate Affairs. Please go ahead.

Jaren Irene Madden;dinger

SchrÃ;Inc. - SVP of IR & Corporate Communications

¶ -

Thank you, and good afternoon, everyone. Welcome to today's call, during which we will provide an update on the company and review our third quarter 2023 financial results. Earlier today, we issued a press release summarizing our results and progress across the company, which is available on our website at schrodinger.com. Here with me on our call today are Ramy Farid, CEO; Geoff Porges, Chief Financial Officer; and Karen Akinsanya, President of R&D, Therapeutics. Following our prepared remarks, we'll open

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.